|The CD134/OX40 tnfrsf4 (Catalog #MBS490105) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s CD134/OX40 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Immunoprecipitation (IP), Flow Cytometry (FC/FACS), ELISA. Researchers should empirically determine the suitability of the CD134/OX40 tnfrsf4 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The CD134/OX40 tnfrsf4 product has the following accession number(s) (GI #197253271) (NCBI Accession #ACH54080.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
CD134/OX40 is a receptor of OX40 ligand (OX40L) transactivated by Tax of HTLV-1. OX40 is expressed in activated CD4+ and CD8+ T cells. OX40 on the activated T cells have a role in proliferation of T cells and production of cytokines by binding with OX40L expressed on antigen presenting cells like dendritic cells or activated B cells. In addition, it also be involved in activated T cell invasion to inflamed area through the binding with OX40L.
Immunogen: Recombinant soluble OX40. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CD134/OX40 are readily searchable from our website. Different antibodies against the same target such as CD134/OX40 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.